AEON Biopharma Receives Additional NYSE American Noncompliance Notice

AEON Biopharma ( (AEON) ) has issued an announcement.

On March 31, 2026, AEON Biopharma received an additional notice from NYSE American that it is not in compliance with Section 1003(a)(ii), which requires at least $4 million in stockholders’ equity when a company has losses in three of its four most recent fiscal years. The exchange’s determination was based on AEON’s reported stockholders’ deficit of about $55 million as of December 31, 2025, and recurring losses detailed in its Form 10-K filed on March 30, 2026.

This notice follows an earlier 2025 deficiency finding under Section 1003(a)(i) and occurs while AEON is operating under an NYSE American–approved remediation plan that runs through August 3, 2026. The latest notice does not immediately affect the listing of AEON’s common stock, which will continue to trade on NYSE American under the symbol AEON with a “.BC” below-compliance indicator, but the company remains on the exchange’s noncompliant issuers list and faces potential delisting if it fails to regain compliance within the plan period.

The most recent analyst rating on (AEON) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on AEON Biopharma stock, see the AEON Stock Forecast page.

Spark’s Take on AEON Stock

According to Spark, TipRanks’ AI Analyst, AEON is a Neutral.

The score is held back primarily by weak financial performance (limited/absent revenue, persistent cash burn, negative equity and leverage risk). Offsetting factors include improving technical momentum, a low reported P/E (though less reliable given earnings volatility), and a positive corporate update around regulatory progress and debt reduction/financing actions.

To see Spark’s full report on AEON stock, click here.

More about AEON Biopharma

AEON Biopharma, Inc. is a biopharmaceutical company focused on the U.S. therapeutic neurotoxin market, seeking full-label access via biosimilarity to BOTOX. Its lead product candidate, ABP-450 (prabotulinumtoxinA), is the same botulinum toxin complex marketed cosmetically as Jeuveau and is approved as a biosimilar in India, Mexico, and the Philippines.

ABP-450 is manufactured by Daewoong Pharmaceutical in an FDA-, Health Canada-, and EMA-authorized facility for botulinum toxin products. AEON holds exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories.

Average Trading Volume: 146,809

Technical Sentiment Signal: Sell

Current Market Cap: $22.49M

See more data about AEON stock on TipRanks’ Stock Analysis page.